Cartalax for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Cartalax for Health & Longevity

Created on 09/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A three-amino-acid peptide aimed at cartilage. In dishes of aged human cells it shifts the activity of genes tied to cartilage building and cellular aging. No controlled study in people has measured joint pain, joint function or safety. Nearly all work comes from the one institute that sells it. The clearest documented hazard is the unregulated market supplying it. (Full Review)

Protocol

Injectable course
1–2 mg subcutaneously, once daily
10–20 consecutive days, repeated two to three times per year. Protocols in circulation, none from a published trial.
Best time of day
Morning, on an empty stomach
No chronobiological data exist. Convention rather than evidence; no trial has compared morning with evening administration.
Single versus split dosing
Single daily dose
No comparison exists. A split schedule has no supporting rationale given a transcriptional rather than concentration-dependent effect.
Time to effect
Time to effect
Unknown; at least two months
No study has measured onset of any human effect. A full course plus several weeks is implied before any judgement is possible.
Intended duration
10–20 days per course
Course-based rather than lifelong, on the premise that a transcriptional effect persists after the peptide is cleared.
Cycling for efficacy
Two to three courses per year
Multi-month gaps. No study has compared cycled with continuous use; the interval reflects convention and exposure caution.

Benefits

Contraindications
  • Active malignancy, or in remission for under five years
  • Pregnancy or breastfeeding
  • Immunocompromised, including transplant recipients on maintenance immunosuppression and absolute neutrophil count below 1,000 cells per microlitre
  • Suspected septic joint, unexplained fever, or unevaluated new joint pain with swelling
  • Severe hepatic impairment (Child-Pugh Class C) or severe kidney impairment (estimated glomerular filtration rate under 30 mL/min/1.73 m²)
Key Interactions
  • Prescription growth-signalling agents: growth hormone (somatropin), IGF-1 analogues (mecasermin)
  • Prescription immunosuppressants: methotrexate, tacrolimus, prednisone
  • Over-the-counter analgesics: non-steroidal anti-inflammatory drugs (ibuprofen, naproxen), paracetamol
  • Supplements with additive effects: collagen peptides, undenatured type II collagen, glucosamine, chondroitin
  • Other intervention interactions: intra-articular corticosteroid and hyaluronic acid injections

Risk & Side Effects

  • Low: Substandard, contaminated or misdosed product; bypassed clinical oversight and delayed diagnosis
  • Speculative: Growth-factor signalling in undetected cancer; sustained NF-κB activation; injection-site reactions and sterile-technique failure

Monitoring

Marker Target Why
hs-CRP Below 1.0 mg/L Systemic inflammatory load that accelerates cartilage loss
ESR Below 15 mm/h (men), below 20 mm/h (women) Separates degenerative joint pain from inflammatory arthritis
Serum COMP No established target; track change from own baseline Reflects cartilage matrix turnover, the process the peptide is proposed to shift
Urinary CTX-II No established target; track change from own baseline Direct readout of type II collagen breakdown in cartilage
Serum IGF-1 120–200 ng/mL, interpreted against age-specific norms Baseline for the unresolved growth-signalling concern
25-hydroxyvitamin D 40–60 ng/mL Identifies a correctable nutritional driver of joint and bone symptoms
eGFR Above 90 mL/min/1.73 m² Organ-function baseline before any self-sourced injectable
Complete blood count with differential Within laboratory reference range Detects infection or marrow suppression after injections from unverified sources

Cadence: Baseline before a first course; complete blood count and inflammatory markers again at 2 weeks; full panel at 3 months; then every 6 to 12 months while courses continue. Any fever or spreading injection-site reaction triggers immediate testing outside that schedule.

Qualitative Assessment

  • Joint pain at rest and on loading, scored 0 to 10 on the same activity each week
  • Morning stiffness duration in minutes, recorded on waking
  • Stair descent and floor-to-stand ability, the functions that degrade first in knee and hip osteoarthritis
  • Energy and recovery after training sessions of comparable load
  • Sleep quality, since disturbed sleep both amplifies pain perception and confounds it
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.